Quick Answer
Zomedica Corp. reported Research And Development Expense of $7.17 million for the year ending 2025.
- Zomedica Corp. showed a decrease of -1.4% in Research And Development Expense from 2024 to 2025.
- This data is from Zomedica Corp.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $616.4 thousand | Q2 2017: $504.2 thousand | Q3 2017: $465.5 thousand | Q1 2018: $600.3 thousand | Q2 2018: $2.53 million | Q3 2018: $630.4 thousand | Q1 2019: $7.53 million | Q2 2019: $1.06 million | Q3 2019: $962.5 thousand | Q1 2020: $630.1 thousand | Q2 2020: $3.91 million | Q3 2020: $2.70 million | Q1 2021: $412.0 thousand | Q2 2021: $271.0 thousand | Q3 2021: $289.0 thousand | Q1 2022: $351.0 thousand | Q2 2022: $319.0 thousand | Q3 2022: $1.22 million | Q1 2023: $918.0 thousand | Q2 2023: $859.0 thousand | Q3 2023: $867.0 thousand | Q1 2024: $1.77 million | Q2 2024: $1.51 million | Q3 2024: $1.85 million | Q1 2025: $1.85 million | Q2 2025: $1.89 million | Q3 2025: $1.78 million.
- Over the full 10 years of available data (2016 to 2025), Zomedica Corp.'s Research And Development Expense has grown by 371.9%.
- Historical annual values: Fiscal year 2025: $7.17 million | Fiscal year 2024: $7.27 million | Fiscal year 2023: $5.74 million | Fiscal year 2022: $2.58 million | Fiscal year 2021: $1.67 million | Fiscal year 2020: $8.04 million | Fiscal year 2019: $10.35 million | Fiscal year 2018: $10.32 million | Fiscal year 2017: $2.75 million | Fiscal year 2016: $1.52 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: